FIELD: pharmaceuticals.
SUBSTANCE: invention relates to a method of producing co-crystalline forms of theobromine with meglumine and theobromine with tromethamine, where the molar ratio in both cases is 1:1, having peaks at 2θ (°) 7.1537, 8.7228, 9.8027, 12.2524, 15.7677, 17.6967, 19.7111, 21.7759, 23.8743, 26.7889, 28.2331, 36.0912, 37.2491, 41.31 83, 45.6465, 51.4422, 56.4172, 61.5586, 63.7719, 66.0422 and peaks at 2θ (°) 14.0683, 18.1478, 20.0967, 22.4362, 25.1774, 28.5611, 31.8306, 33.7598, 33.9691, 36.5068, 38.2442, 38.3167, 38.4844, 41.9036, 43.2730, 45.6545 according to X-ray diffraction measurements of a polycrystal, respectively, by the method of mechanochemical activation, carried out by supplying a mixture of theobromine with meglumine or theobromine with tromethamine in a planetary porcelain ball mill. Then they are subjected to mechanical action in the presence of methanol, after which the target products are purified by recrystallization from methanol by adsorption of impurities with activated carbon, hot filtration and cooling of the resulting solution.
EFFECT: obtaining co-crystalline forms of theobromine with meglumine or tromethamine, characterized by a high degree of solubility.
1 cl, 10 dwg, 1 tbl, 1 ex
Title | Year | Author | Number |
---|---|---|---|
CO-CRYSTALLINE FORMS OF THEOPHYLLINE | 2022 |
|
RU2805752C2 |
CO-CRYSTALLINE FORM OF THEOPHYLLINE WITH DIFLUNISAL OR DICLOFENAC | 2013 |
|
RU2542100C1 |
COCRYSTALLINE FORM OF NIFLUMIC ACID WITH ISONICOTINAMIDE OT CAFFEINE | 2013 |
|
RU2536484C1 |
CO-CRYSTALLINE FORM OF 2-HYDROXYBENZAMIDE WITH SALICYLIC ACID | 2013 |
|
RU2539350C1 |
CO-CRYSTALLINE FORM OF 2-HYDROXYBENZAMIDE AND 4-AMINOBENZOIC ACID | 2012 |
|
RU2497804C1 |
CO-CRYSTALLINE FORM OF BICALUTAMIDE | 2012 |
|
RU2510392C1 |
COCRYSTALLINE FORM OF FENBUFEN | 2012 |
|
RU2521572C1 |
DIFLUNISAL CO-CRYSTALLINE FORM | 2016 |
|
RU2617849C1 |
CO-CRYSTALLINE FORM OF ISONIAZID | 2016 |
|
RU2630957C1 |
PARECOXIB SODIUM CRYSTALLINE SALT | 2003 |
|
RU2300529C2 |
Authors
Dates
2023-10-23—Published
2022-03-01—Filed